AbbVie Inc. (ABBV) Price History:19.18%(TTM)
The price cagr for AbbVie Inc. (ABBV) is +19.18% over the latest trailing 12-month period. The comparable SPY value is +22.92%. Year-to-date price return is -1.70%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$225.42
+$2.35 (+1.05%)
Previous Close: $223.07
Today's Trading
- Open
- $224.80
- Day High
- $227.14
- Day Low
- $221.72
- Volume
- 4.06M
- Avg Volume
- N/A
52-Week Position
69%
of the 52-week price range
- From 52-week high
- -7.92%
- From 52-week low
- +24.04%
52-Week Price Range
52-Week Low
$181.73
Jun 27, 2025
Current Price
$225.42
69% of range
52-Week High
$244.81
Oct 1, 2025
Price Returns by Period
1 Day
+1.05%
7 Days
+4.65%
30 Days
+11.84%
YTD
-1.70%
1 Year
+19.17%
vs 52W High
-7.92%
ABBV Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
+17.72%
Price CAGR (5Y)
+14.61%
Total Return CAGR (3Y)
+22.04%
Total Return CAGR (5Y)
+19.01%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $225.42 |
| Previous Close | $223.07 |
| Day Range | $221.72 - $227.14 |
| 52-Week Range | $181.73 - $244.81 |
| Volume | 4.06M |
| Average Volume | N/A |
| Market Cap | $398.27B |
| % from 52W High | -7.92% |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael